Table 2.
Vaccine-specific model parameters
| Parameter | PHiD-CV | PCV13 | Rangea | PSA distribution |
|---|---|---|---|---|
| Vaccination ages (months) | 2, 4 and 13 | 2, 4 and 13 | Not varied | NA |
| Vaccination coverage (%) | 100 [28] | 100 [28] | Not varied | NA |
| Vaccine cost (USD/dose) | 34.25 (hypothetical price) | 34.25 (hypothetical price) | Not varied | NA |
| VEs/effectivenesses (%) | ||||
| IPD | ||||
| Vaccine serotypes (excluding ST3) | 94.7 (based on PCV7 data [31]) | 94.7 (based on PCV7 data [31]) | 95% CIb | Lognormal |
| ST3 | 0 (assumption) | 26 (based on PCV13 data [32]) | Not varied | NA |
| Cross-protection for ST6A | 76.0 (based on PCV7 data [31, 36]) | NA | 95% CIc | Lognormal |
| Cross-protection for ST19A | 82.2 (based on PHiD-CV surveillance [14]) | NA | 95% CIc | Lognormal |
| All-cause pneumonia | ||||
| Hospitalized | 21.8 (based on PHiD-CV data [17]) | 21.8 (based on PHiD-CV data [17]) | 95% CI | Lognormal |
| GP visit | 8.7 (based on PHiD-CV data [17]) | 8.7 (based on PHiD-CV data [17]) | 95% CI | Lognormal |
| All-cause AOM | ||||
| Vaccine serotypes (excluding ST3) | 69.9 (based on PHiD-CV data [17]) | 69.9 (based on PHiD-CV data [17]) | 95% CI | Lognormal |
| Cross-protection for ST6A | 63.7 (based on PHiD-CV precursor data [18]) | NA | Not variedc | NA |
| Cross-protection for ST19A | 61 (based on PHiD-CV and PCV7 data [14, 17, 31])d | NA | Not variedc | NA |
| ST3 | 0 (assumption) | 0 (assumption due to a lack of relevant data) | Not varied | NA |
| Non-vaccine serotypes | –33 (based on PCV7 data [43]) | –33 (based on PCV7 data [43]) | 95% CI | Lognormal |
| NTHi | 21.5 (based on PHiD-CV data [17]) | –11 (based on PCV7 data [43]) | 95% CI | Lognormal |
| Overall | 24.1 (based on the above and pathogen split from [41, 42]) | 14.2 (based on the above and pathogen split from [41, 42]) | Not varied | NA |
AOM acute otitis media, CI, confidence interval, GP general practitioner, IPD invasive pneumococcal disease, NA not applicable, NTHi non-typeable Haemophilus influenzae, PCV7 7-valent pneumococcal conjugate vaccine, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV pneumococcal polysaccharide and NTHi protein D conjugate vaccine, ST serotype, USD United States dollars, VE vaccine efficacy, PSA probabilistic sensitivity analysis
aRanges used in the one-way sensitivity analyses
bLowest and highest vaccine-type 95% CIs from [31] used for all serotypes
cNot applicable for PCV13
dEstimated based on PHiD-CV VE against 19A IPD [14], PCV7 VE against vaccine serotype IPD [31], and PHiD-CV VE against vaccine serotype AOM [17]